Design Therapeutics reports lower-than-expected Q4 net loss

Design Therapeutics

09/03/2026 20:13

Overview

Biotechnology firm's Q4 net loss of $16 mln beat analyst expectations

Cash position of $219.8 mln expected to fund operations into 2029

Outlook

Design Therapeutics expects cash to fund operations into 2029

Result Drivers

CASH POSITION - Co reported $219.8 mln in cash and securities, expected to fund operations into 2029

Company press release: ID:nGNXc8QCWm

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Net Income
Beat
-$16 mln
-$20.31 mln (5 Analysts)
Q4 Basic EPS
-$0.27
Q4 Operating Expenses
$18.17 mln
Q4 Operating Income
-$18.17 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Design Therapeutics Inc is $13.00, about 29.4% above its March 6 closing price of $10.05

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)